$ALNY
AI 分析生成於 May 11, 2026
AI Score
Hold$ALNY
Alnylam Pharmaceuticals
$ALNYNASDAQHealthcareLarge-Cap
Alnylam pioneers RNAi therapeutics for genetic diseases with Onpattro, Givlaari, and Oxlumo.
Market Cap
$32.0B
Revenue (TTM)
$2.5B
+45.0%
Net Income (TTM)
$0.1B
N/A
EPS (TTM)
$0.50
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$150-$270
Beta
0.72
Dimension Scores
Fundamental
60Technical
64Sentiment
74Risk / Reward
58Momentum
78Financial Health
Profitability
65moderate
Growth
81strong
Liquidity
66strong
Solvency
62moderate
Efficiency
58moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $ALNY
Free · No credit card required
免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。